1 Sebille V, Bellissant E.Comparison of four sequential methods allowing for early stopping of comparative clinical trials[J].Clinical Science, 2000;98:569-78
2 Van der Tweel I, Schipper M.Sequential analysis in clinical and epidemiological research[J].Ned Tijdschr Geneeskd, 2002;146:2348-52
3 International Conference On Harmonisation.Guidance on statistical principles for clinical trials;Availability.Department of health and human services FDA[J].Federal Register, 1998;63:49583-98
4 Pocock SJ.GrouPsequential methods in the design and analysis of clinical trials[J].Biometrika, 1977;64:191-9
5 O' Brien PC, Fleming TR.A multiple testing procedure for clinical trials[J].Biometrics, 1979;35:549-56
6 Lan KKG, DeMets DL.Discrete sequential boundaries for clinical trials[J].Biometrika, 1983;70:659-63
7 Wang SK, Tsiatis AA.Approximately optimal one-parameter boundaries for grouPsequential trials[J].Biometrics, 1987;43:193-9
8 Geller NL, Pocock SJ.Interim analyses in randomized clinical trials:ramifications and guidelines for practitioners[J].Biometrics,1987;43:213-23
9 徐勇勇, 赵清波.临床试验的期中分析与成组序贯设计[J].中国卫生统计, 1992;9:56-9
10 何清波, 苏炳华.成组序贯试验的原理和方法[J].现代预防医学, 1999;26:310-2
11 郭静, 何大卫.期中分析方法在临床试验中的应用[J].山西医科大学学报, 2001;32:506-9
12 Skovlund E.Repeated significance tests on accumulating survival data[J].J Clin Epidemiol, 1999;52:1083-8
13 McPherson CK.On choosing the number of interim analysis in clinical trials[J].Statistics in medicine, 1982;1:25-36
14 Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, et al.Design and analysis of randomized clinical trials requiring prolonged observation of each patient.II.analysis and examples[J].Br J Cancer, 1977;35:1-39
15 Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, et al.Design and analysis of randomized clinical trials requiring prolonged observation of each patient I.Introduction and design[J].Br J Cancer, 1976;34:585-612
16 Jennison C, Turnbull BW.Repeated confidence intervals for grouPsequential clinical trials[J].Control Clin Trials, 1984;5:33-45
17 Emerson SS, Fleming TR.Symmetric grouPsequential test designs[J].Biometrics, 1989;45:905-23
18 Pocock SJ.Interim analyses for randomized clinical trials:the grouPsequential approach[J].Biometrics, 1982;38:153-62
19 Chen YH, DeMets DL, Lan KK.Monitoring mortality at interim analyses while testing a composite endpoint at the final analysis[J].Control Clin Trials, 2003;24:16-27
20 Pilote L, Califf RM, SapPS, Miller DP, Mark DB, Weaver WD,et al.Regional variation across the United States in the management of acute myocardial infarction.GUSTO-1 Investigators.Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries[J].N Engl J Med, 1995;333:565-72
21 Tang DI, Geller NL, Pocock SJ.On the design and analysis of randomized clinical trials with multiple endpoints[J].Biometrics,1993;49:23-30
22 Pocock SJ, Geller NL, Tsiatis AA.The analysis of multiple endpoints in clinical trials[J].Biometrics, 1987;43:487-98
23 PackerM, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, et al.The effect of carvedilol on morbidity and mortality in patients with chronic heart failure.U.S.Carvedilol Heart Failure Study Group[J].N Engl J Med, 1996;334:1349-55
24 Whitehead J.Sequential methods based on the boundaries approach for the clinical comparison or survival times[J].Statistics in medicine, 1994;13:1357-68
25 Choi SC.Interim analyses and early termination of clinical trials [J].J Biopharm Stat, 1997;7:533-43
26 Skovlund E.Repeated significance tests on accumulating survival data[J].J Clin Epidemiol, 1999;52:1083-8
27 Elashoff JD, Reedy TJ.Two-stage clinical trial stopping rules[J].Biometrics, 1984;40:791-5 |
